A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis

The purpose of this study is to assess the measurable changes in health, function, or quality of life (clinical outcomes) after receiving guselkumab in real-world clinical practice amongst Chinese participants with ulcerative colitis (UC; a long-term disease of the large intestine in which the lining of the colon \[part of large intestine\] becomes inflamed and develops tiny open ulcers), who have not received biologic therapy (a medicine made from living organisms or their components) previously.

NCT Number	NCT07302360
Lead Sponsor	Xian-Janssen Pharmaceutical Ltd.
Conditions	Colitis, Ulcerative
Enrollment	200 participants
Start Date	2025-12-11
Primary Completion	2028-06-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-31